[{"id":"4af37b5e-53c0-463d-aa29-d4176aa0cac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04637503","created_at":"2021-01-19T20:37:37.669Z","updated_at":"2024-07-02T16:36:38.465Z","phase":"Phase 1/2","brief_title":"4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma","source_id_and_acronym":"NCT04637503","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T • GD2, PSMA and CD276 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-11-19"},{"id":"0f73e762-cc4d-4587-b6bb-5b28a5196876","acronym":"","url":"https://clinicaltrials.gov/study/NCT04430530","created_at":"2021-01-18T21:20:13.869Z","updated_at":"2024-07-02T16:36:44.211Z","phase":"Phase 1/2","brief_title":"4SCAR-T Therapy Post CD19-targeted Immunotherapy","source_id_and_acronym":"NCT04430530","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD38 • CD123 • CD22 • MME • IL3RA","pipe":"","alterations":" ","tags":["CD20 • CD38 • CD123 • CD22 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"},{"id":"8ecd0d5a-4acf-4233-aeb0-ac0394f32647","acronym":"","url":"https://clinicaltrials.gov/study/NCT04430595","created_at":"2021-01-18T21:20:15.327Z","updated_at":"2024-07-02T16:36:44.254Z","phase":"Phase 1/2","brief_title":"Multi-4SCAR-T Therapy Targeting Breast Cancer","source_id_and_acronym":"NCT04430595","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • CD44 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CD44 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"},{"id":"0c9e63e6-e013-4d60-9884-43f80b3ef7f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04016129","created_at":"2021-01-18T19:43:30.822Z","updated_at":"2024-07-02T16:36:55.506Z","phase":"Phase 1/2","brief_title":"CAR-T Immunotherapy Targeting CD19- ALL","source_id_and_acronym":"NCT04016129","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA","pipe":"","alterations":" ","tags":["CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2019-09-19"}]